Evidence that Replication of the Antitumor Adenovirus ONYX-015 Is Not Controlled by the p53 and p14(ARF) Tumor Suppressor Genes
The adenovirus mutant ONYX-015 is in phase III clinical trials as a novel antitumor therapy. Its apparent efficacy is thought to be due to its ability to replicate selectively in tumor cells defective in the signaling pathway for p53. Recent data have shown that p14(ARF), a positive regulator of p53...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | J Virol |
|---|---|
| Prif Awduron: | , , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
American Society for Microbiology (ASM)
2002
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC136704/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/12438574/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/JVI.76.24.12483-12490.2002 |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|